HRP20161178T1 - N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE - Google Patents
N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE Download PDFInfo
- Publication number
- HRP20161178T1 HRP20161178T1 HRP20161178TT HRP20161178T HRP20161178T1 HR P20161178 T1 HRP20161178 T1 HR P20161178T1 HR P20161178T T HRP20161178T T HR P20161178TT HR P20161178 T HRP20161178 T HR P20161178T HR P20161178 T1 HRP20161178 T1 HR P20161178T1
- Authority
- HR
- Croatia
- Prior art keywords
- oxo
- carbonyl
- spiro
- tetrahydro
- indazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38810210P | 2010-09-30 | 2010-09-30 | |
| PCT/IB2011/054119 WO2012042433A1 (en) | 2010-09-30 | 2011-09-20 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
| EP11768163.5A EP2621493B1 (en) | 2010-09-30 | 2011-09-20 | N1-PYRAZOLOSPIROKETONE ACETYL-CoA CARBOXYLASE INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161178T1 true HRP20161178T1 (hr) | 2016-11-04 |
Family
ID=44789556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161178TT HRP20161178T1 (hr) | 2010-09-30 | 2011-09-20 | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
Country Status (15)
| Country | Link |
|---|---|
| US (8) | US8859577B2 (enExample) |
| EP (1) | EP2621493B1 (enExample) |
| JP (1) | JP5824055B2 (enExample) |
| CA (1) | CA2811033C (enExample) |
| CY (1) | CY1118016T1 (enExample) |
| DK (1) | DK2621493T3 (enExample) |
| ES (1) | ES2602111T3 (enExample) |
| HR (1) | HRP20161178T1 (enExample) |
| HU (1) | HUE031616T2 (enExample) |
| LT (1) | LT2621493T (enExample) |
| PL (1) | PL2621493T3 (enExample) |
| PT (1) | PT2621493T (enExample) |
| RS (1) | RS55224B1 (enExample) |
| SI (1) | SI2621493T1 (enExample) |
| WO (1) | WO2012042433A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040198483A1 (en) | 2003-04-03 | 2004-10-07 | Amaitis Lee M. | System and method for betting on a subset of participants in an event |
| US8636571B2 (en) | 2004-02-03 | 2014-01-28 | Cantor Index, Llc | System and method for managing select five horseracing bets |
| US9098883B2 (en) | 2004-02-03 | 2015-08-04 | Cantor Index, Llc | Managing bets that select events and participants |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| AP3283A (en) | 2009-11-10 | 2015-05-31 | Pfizer | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| HRP20161178T1 (hr) | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| SG189883A1 (en) * | 2010-10-29 | 2013-06-28 | Pfizer | N1/N2-LACTAM ACETYL-CoA CARBOXYLASE INHIBITORS |
| PT2699576E (pt) * | 2011-04-22 | 2016-03-09 | Pfizer | Derivados de pirazoloespirocetona para utilização como inibidores de acetil-coa carboxilase |
| US8905832B2 (en) | 2012-01-30 | 2014-12-09 | Cfph, Llc | Event wagering with group and/or in run options |
| US11055967B2 (en) | 2014-03-26 | 2021-07-06 | Cfph, Llc | Event wagering with group and/or in run options |
| US20170178994A1 (en) * | 2015-12-21 | 2017-06-22 | Intel Corporation | Integrated circuit package support structures |
| KR102579876B1 (ko) | 2016-02-22 | 2023-09-18 | 삼성전자주식회사 | 반도체 패키지 |
| US11478440B2 (en) * | 2017-04-18 | 2022-10-25 | Genfit | Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent |
| JP7237082B2 (ja) | 2017-11-21 | 2023-03-10 | ファイザー・インク | ４－（４－（１－イソプロピル－７－オキソ－１，４，６，７－テトラヒドロスピロ［インダゾール－５，４’－ピペリジン］－１’－カルボニル）－６－メトキシピリジン－２－イル）安息香酸の２－アミノ－２－（ヒドロキシメチル）プロパン－１，３－ジオール結晶塩 |
| CA3045644C (en) | 2018-06-13 | 2024-01-16 | Pfizer Inc. | Glp-1 receptor agonists and uses thereof |
| CR20210110A (es) * | 2018-08-31 | 2021-05-13 | Pfizer | Combinaciones para tratamiento de ehna/ehgna y enfermedades relacionadas |
| EP4578460A3 (en) * | 2019-05-20 | 2025-08-27 | Pfizer Inc. | Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases |
| CN110183456A (zh) * | 2019-07-11 | 2019-08-30 | 河南师范大学 | 一种2-芳基吲唑琥珀酰亚胺螺环化合物的合成方法 |
| AU2020402177A1 (en) | 2019-12-10 | 2022-06-16 | Pfizer Inc. | Solid forms of 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo(d) (1,3)dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo(d) imidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
| WO2021155841A1 (en) | 2020-02-07 | 2021-08-12 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2021134211A (ja) * | 2020-02-24 | 2021-09-13 | ファイザー・インク | Ｎａｆｌｄ／ｎａｓｈおよび関連疾患の処置のための組合せ |
| JP2022058085A (ja) | 2020-02-24 | 2022-04-11 | ファイザー・インク | ジアシルグリセロールアシルトランスフェラーゼ２阻害剤とアセチル－ＣｏＡカルボキシラーゼ阻害剤との組合せ |
| BR112022017578A2 (pt) | 2020-03-27 | 2022-10-18 | Pfizer | Tratamento do diabetes tipo 2 ou obesidade ou sobrepeso com ácido 2-[(4-{6-[(4-ciano-2-fluorobenzil)óxi]piridin-2-il}piperidin-1-il)metil]-1-[(2s)-oxetan-2-ilmetil]-1h-benzimidazol-6-carboxílico ou um sal farmacêutico do mesmo |
| CA3230347A1 (en) | 2021-08-31 | 2023-03-09 | Pfizer Inc. | Solid forms of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid, 1,3-dihydroxy-2-(hydroxymethyl)propan-2-amine salt |
| EP4490155A1 (en) | 2022-03-09 | 2025-01-15 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| JP2025513071A (ja) | 2022-04-14 | 2025-04-22 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| WO2023228023A1 (en) | 2022-05-23 | 2023-11-30 | Pfizer Inc. | Treatment of type 2 diabetes or weight management control with 2-((4-((s)-2-(5-chloropyridin-2-yl)-2-methylbenzo[d][1,3]dioxol-4-yl)piperidin-1-yl)methyl)-1-(((s)-oxetan-2-yl)methyl)-1h-benzo[d]imidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| CN120129681A (zh) | 2022-10-18 | 2025-06-10 | 辉瑞大药厂 | 含Patatin样磷脂酶结构域的蛋白3（PNPLA3）调节剂 |
| AU2023396387A1 (en) | 2022-12-15 | 2025-06-26 | Gasherbrum Bio, Inc. | Salts and solid forms of a compound having glp-1 agonist activity |
| WO2025099561A1 (en) | 2023-11-07 | 2025-05-15 | Pfizer Inc. | Oral controlled-release matrix formulations of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
| WO2025224648A1 (en) | 2024-04-26 | 2025-10-30 | Pfizer Inc. | Oral compositions/formulations of 2-({4-[(2s)-2-(4-chloro-2-fluorophenyl)-2-methyl-1,3-benzodioxol-4-yl]piperidin-1-yl}methyl)-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE364374T1 (de) | 1997-08-11 | 2007-07-15 | Pfizer Prod Inc | Feste pharmazeutische dispersionen mit erhöhter bioverfügbarkeit |
| DE60219295T2 (de) | 2001-02-28 | 2008-01-03 | Merck & Co., Inc. | Acylierte piperidinderivate als melanocortin-4-rezeptoragonisten |
| ES2246481T3 (es) | 2002-02-27 | 2006-02-16 | Pfizer Products Inc. | Inhibidores de la acc. |
| US7105526B2 (en) | 2002-06-28 | 2006-09-12 | Banyu Pharmaceuticals Co., Ltd. | Benzimidazole derivatives |
| WO2004092179A1 (ja) | 2003-04-14 | 2004-10-28 | Nippon Soda Co. Ltd. | スピロ誘導体、製造法および抗酸化薬 |
| JP2005119987A (ja) | 2003-10-15 | 2005-05-12 | Ajinomoto Co Inc | アシルスルホンアミド誘導体 |
| WO2005113069A2 (en) | 2004-05-14 | 2005-12-01 | Research Development Foundation | Use of circumin and analogues as inhibitors of acc2 |
| JP4069159B2 (ja) | 2004-05-25 | 2008-04-02 | ファイザー・プロダクツ・インク | テトラアザベンゾ［ｅ］アズレン誘導体及びそれらのアナログ |
| PA8660701A1 (es) | 2005-02-04 | 2006-09-22 | Pfizer Prod Inc | Agonistas de pyy y sus usos |
| US7935712B2 (en) | 2005-07-19 | 2011-05-03 | Merck Sharp & Dohme Corp. | Spirochromanone derivatives as acetyl coenzyme A carboxylase (ACC) inhibitors |
| EP1911753A1 (en) | 2005-07-29 | 2008-04-16 | Takeda Pharmaceutical Company Limited | Spiro-cyclic compound |
| DE102006016566B4 (de) | 2005-09-22 | 2008-06-12 | Beru Ag | Zusammengesetzter Leiter, insbesondere für Glühkerzen für Dieselmotoren |
| CA2629406A1 (en) | 2005-11-18 | 2007-05-31 | Merck & Co., Inc. | Spirohydantoin aryl cgrp receptor antagonists |
| US8735595B2 (en) | 2006-02-15 | 2014-05-27 | Abbvie Inc. | Acetyl-CoA carboxylase (ACC) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| RS20090249A (sr) | 2006-11-29 | 2010-06-30 | Pfizer Products Inc. | Spiroketon inhibitori acetil-coa karboksilaze |
| WO2008088692A2 (en) * | 2007-01-12 | 2008-07-24 | Merck & Co., Inc. | Spirochromanon derivatives |
| PE20081559A1 (es) | 2007-01-12 | 2008-11-20 | Merck & Co Inc | DERIVADOS DE ESPIROCROMANONA SUSTITUIDOS COMO INHIBIDORES DE ACETIL CoA CARBOXILASA |
| EP2123652A1 (en) * | 2007-02-20 | 2009-11-25 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| MX2009010951A (es) | 2007-04-12 | 2009-10-29 | Pfizer | Derivados de 3-amino-pirrolo[3,4-c]pirazol-5(1h,4h,6h)-carbaldehid o como inhibidores de proteina quinasa c. |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| JP5435592B2 (ja) | 2008-05-28 | 2014-03-05 | ファイザー・インク | ピラゾロスピロケトンアセチルＣｏＡカルボキシラーゼ阻害剤 |
| US20110009443A1 (en) | 2008-05-28 | 2011-01-13 | Kevin Daniel Freeman-Cook | Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors |
| US8524730B2 (en) | 2008-07-04 | 2013-09-03 | Msd K.K. | Spirochromanone carboxylic acids |
| EP2310015A4 (en) | 2008-07-14 | 2011-10-26 | Cropsolution Inc | ACETYL-COENZYME-CARBOXYLASE MODULATORS AND METHODS OF USE THEREOF |
| AP3283A (en) * | 2009-11-10 | 2015-05-31 | Pfizer | N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors |
| JP2013510191A (ja) | 2009-11-10 | 2013-03-21 | ファイザー・インク | Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬 |
| HRP20161178T1 (hr) * | 2010-09-30 | 2016-11-04 | Pfizer Inc. | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE |
| US20160034775A1 (en) | 2014-08-02 | 2016-02-04 | General Vault, LLC | Methods and apparatus for bounded image data analysis and notification mechanism |
-
2011
- 2011-09-20 HR HRP20161178TT patent/HRP20161178T1/hr unknown
- 2011-09-20 HU HUE11768163A patent/HUE031616T2/hu unknown
- 2011-09-20 WO PCT/IB2011/054119 patent/WO2012042433A1/en not_active Ceased
- 2011-09-20 ES ES11768163.5T patent/ES2602111T3/es active Active
- 2011-09-20 LT LTEP11768163.5T patent/LT2621493T/lt unknown
- 2011-09-20 US US13/876,211 patent/US8859577B2/en active Active
- 2011-09-20 PT PT117681635T patent/PT2621493T/pt unknown
- 2011-09-20 SI SI201130951A patent/SI2621493T1/sl unknown
- 2011-09-20 JP JP2013530829A patent/JP5824055B2/ja active Active
- 2011-09-20 DK DK11768163.5T patent/DK2621493T3/en active
- 2011-09-20 RS RS20160845A patent/RS55224B1/sr unknown
- 2011-09-20 EP EP11768163.5A patent/EP2621493B1/en active Active
- 2011-09-20 CA CA2811033A patent/CA2811033C/en active Active
- 2011-09-20 PL PL11768163T patent/PL2621493T3/pl unknown
-
2014
- 2014-09-19 US US14/491,016 patent/US9145416B2/en active Active
-
2015
- 2015-09-11 US US14/851,572 patent/US20150376185A1/en not_active Abandoned
-
2016
- 2016-08-15 US US15/236,635 patent/US9908883B2/en active Active
- 2016-09-13 CY CY20161100905T patent/CY1118016T1/el unknown
-
2018
- 2018-01-30 US US15/883,109 patent/US10294225B2/en active Active
-
2019
- 2019-04-01 US US16/371,896 patent/US10822335B2/en active Active
-
2020
- 2020-09-28 US US17/034,295 patent/US11673890B2/en active Active
-
2023
- 2023-05-03 US US18/311,715 patent/US20230322777A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| LT2621493T (lt) | 2016-10-25 |
| ES2602111T3 (es) | 2017-02-17 |
| JP5824055B2 (ja) | 2015-11-25 |
| US20150376185A1 (en) | 2015-12-31 |
| HUE031616T2 (hu) | 2017-07-28 |
| US20160347752A1 (en) | 2016-12-01 |
| US10822335B2 (en) | 2020-11-03 |
| US8859577B2 (en) | 2014-10-14 |
| WO2012042433A1 (en) | 2012-04-05 |
| RS55224B1 (sr) | 2017-02-28 |
| US9908883B2 (en) | 2018-03-06 |
| US20150011470A1 (en) | 2015-01-08 |
| US11673890B2 (en) | 2023-06-13 |
| US20190218218A1 (en) | 2019-07-18 |
| US20210047325A1 (en) | 2021-02-18 |
| DK2621493T3 (en) | 2016-10-24 |
| SI2621493T1 (sl) | 2016-10-28 |
| US20130190334A1 (en) | 2013-07-25 |
| CY1118016T1 (el) | 2017-05-17 |
| US10294225B2 (en) | 2019-05-21 |
| PL2621493T3 (pl) | 2017-01-31 |
| CA2811033C (en) | 2015-10-20 |
| US20180162858A1 (en) | 2018-06-14 |
| US20230322777A1 (en) | 2023-10-12 |
| CA2811033A1 (en) | 2012-04-05 |
| US9145416B2 (en) | 2015-09-29 |
| EP2621493A1 (en) | 2013-08-07 |
| JP2013540119A (ja) | 2013-10-31 |
| EP2621493B1 (en) | 2016-08-17 |
| PT2621493T (pt) | 2016-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161178T1 (hr) | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE | |
| JP2013540119A5 (enExample) | ||
| HRP20140025T1 (hr) | N1-PIRAZOLOSPIROKETONSKI INHIBITORI ACETIL-CoA-KARBOKSILAZE | |
| US11591336B2 (en) | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors | |
| US20230227471A1 (en) | Bifunctional compounds for degrading btk via ubiquitin proteosome pathway | |
| RU2017106742A (ru) | Комбинированная терапия для лечения парамиксовируса | |
| US20230158151A1 (en) | Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use | |
| RU2018138050A (ru) | Производные тиазолопиридина как агонисты gpr119 | |
| JP2012525395A5 (enExample) | ||
| RU2016140338A (ru) | Азаспиро производные в качестве антагонистов trpm8 | |
| JP2008519765A5 (enExample) | ||
| HRP20160539T1 (hr) | Antagonisti trpv4 | |
| JP2014521711A5 (enExample) | ||
| JP2010506850A5 (enExample) | ||
| JP2007503443A5 (enExample) | ||
| JP2010515734A5 (enExample) | ||
| RU2012137489A (ru) | Производные 2,3-дигидро-1н-инден-1-ил-2,7-диазаспиро[3.5]нонана и их применение в качестве антагонистов или обратных агонистов грелинового рецептора | |
| JP2021501220A5 (enExample) | ||
| RU2015129538A (ru) | Замещенные имидазопиридины в качестве ингибиторов hdm2 | |
| HRP20171454T1 (hr) | Fuzionirani heterociklični spojevi kao modulatori ionskih kanala | |
| HRP20230595T1 (hr) | Inhibitori lizina specifične demetilaze-1 | |
| AU5816700A (en) | Respiratory syncytial virus replication inhibitors | |
| RU2015114936A (ru) | Ингибиторы серин/треонинкиназы | |
| JP2016507551A5 (enExample) | ||
| AU2008329909A1 (en) | Derivatives of 6,7-dihydro-5H-imidazo[1,2-alpha]imidazole-3- carboxylic acid amides |